🔗 Share this article

As America proceeds with historic revisions to its vaccination schedules, a particular individual has surfaced somewhat surprisingly: Tracy Beth Høeg, a US-based sports medicine doctor and epidemiologist who initially gained attention by questioning Covid shots during the pandemic and has focused upon alleged fatalities after COVID-19 vaccination in her brief time at the Food and Drug Administration.

Proposed Changes to Childhood Vaccine Program

Agency leaders had intended to announce sweeping revisions to the pediatric immunization program in December, bringing the US with the Danish immunization schedule, according to reports – a significant shift that would put the US out of step with much of the global community with no evidence for improved outcomes. The planned update has been delayed until the coming year.

Instead of the director of the vaccine center, Tracy Beth Høeg is listed to present at the event. She was just designated temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to run the office this calendar year.

A Shift at the FDA

The acting appointment may indicate a tighter collaboration between the pharmaceutical and vaccine divisions as Høeg and Prasad strengthen their influence at the regulatory agency – and it signals a increased emphasis upon rolling back long-standing immunizations at the FDA.

The new acting director has frequently advocated for discontinuing specific childhood immunization guidelines in the US in order to be more in line with the Danish model, a society with comprehensive healthcare and a population about the population of Wisconsin’s.

To date public appearances, she has persisted in emphasizing on vaccines – typically the purview of Prasad, chief of the FDA’s CBER – instead of drug regulation.

Doubts Over Qualifications

The appointee has no apparent track record in drug development, oversight or administrative roles, which has been customary for past leaders of the CBER. She has been employed at the FDA as a senior adviser to the commissioner and the vaccine center since March.

“It seems she lacks to have any of the qualifications” for running the CDER, remarked Dr. Jonathan Howard. “She lacks experience running a clinical trial. She lacks experience in managing a major agency. She is not an expert in industry regulation.”

Previous directors of CBER would “understand legal statutes and the research of drug development”, noted Dr. Janet Woodcock. “Frankly, she has not acquired the type of experience that previous people who headed the center have had.”

This division has an enormous workload at the FDA, Woodcock emphasized.

“Everybody just zeroes in on the new drug program, but the generic drug division approves a multitude of generic medications. There is also a biosimilars division, over-the-counter program and so forth, and each of these have to be looked after,” Woodcock explained. “The responsibility you don’t keep your eye on, that’s the thing that I always told people is going to bite you.”

There is also, a substantial administrative component to the role, which oversees more than 5,000 employees. “It is a huge administrative position, if you execute it properly,” she concluded.

Agency Reaction and Disputed Programs

Regarding questions about Dr. Høeg's qualifications and whether this assignment signifies increased cooperation among FDA leaders on vaccines, a representative said that the “inquiries rely on flawed premises”.

“Her experience is consistent with the responsibilities of her position,” the spokesperson explained, noting the months Høeg spent counseling the FDA commissioner on “medication safety and regulatory science, including computational safety modeling and vaccine surveillance”.

As acting director, Dr. Høeg takes over the commissioner’s controversial priority voucher program, a contentious one-day therapy clearance system that reportedly troubled her former heads. “How are these medications being picked for this expedited pathway? Who is making the choices?” Howard asked. “There is a lot of secrecy going on at the regulatory body right now.”

Broadly speaking, he said, “the Food and Drug Administration looks to be trending towards laxer rules of pharmaceuticals, except for immunizations.”

Established History on Vaccines

Concerning vaccines, Høeg has a clearer, if troubling, track record, critics said. She released a research paper using unverified public submissions to assess the frequency of heart inflammation following Covid vaccination. She counseled the state of Florida surgeon general Joseph Ladapo, who was said to have altered data to indicate Covid vaccines are riskier than they are.

Among her “policy goals” for the new administration encompassed revising rules for new vaccines and halting “non-essential” vaccines, she said post-election on a podcast. At the agency, Høeg has reportedly proposed preventing young men from obtaining Covid vaccines.

“She is an thorough dogmatist who begins with her conclusions and reverse-engineers to accommodate the evidence in a highly deceptive, dishonest manner,” Howard stated.

Consolidating Power and a “Push for Payback”

Dr. Høeg joined other contrarians, {like|